PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...

You might be interested in a way to run powerful large language models (LLMs) directly on your own hardware, without the recurring fees or privacy concerns. That’s where Ollama comes in—a ...

Large-growth funds posted strong gains in 2024, thanks partly to the artificial intelligence boom. Despite slipping in December, the average large-growth fund beat the broader market last year.